Woman and Man | 18 years and more
- | Country :
- France
- | organs :
- Primitif du foie
- | Specialty :
- Thérapies Ciblées
Extract
A phase II open label study of brivanib (BMS582664), administered orally at a dose of 800 mg daily in subjects with unresectable, locally advanced or metastatic hepatocellular carcinoma who have received either no prior systemic therapy or one prior regimen of angiogenesis inhibitor therapy.
Scientific Abstract
en cours d'intégration;